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Summary
Background Many people with epilepsy in low-income countries do not receive appropriate biomedical treatment. 
This epilepsy treatment gap might be caused by patients not seeking biomedical treatment or not adhering to 
prescribed antiepileptic drugs (AEDs). We measured the prevalence of and investigated risk factors for the epilepsy 
treatment gap in rural Kenya.
Methods All people with active convulsive epilepsy identiﬁ ed during a cross-sectional survey of 232 176 people in 
Kiliﬁ  were approached. The epilepsy treatment gap was deﬁ ned as the percentage of people with active epilepsy 
who had not accessed biomedical services or who were not on treatment or were on inadequate treatment. 
Information about risk factors was obtained through a questionnaire-based interview of sociodemographic 
characteristics, socioeconomic status, access to health facilities, seizures, stigma, and beliefs and attitudes about 
epilepsy. The factors associated with people not seeking biomedical treatment and not adhering to AEDs were 
investigated separately, adjusted for age.
Findings 673 people with epilepsy were interviewed, of whom 499 (74%) reported seeking treatment from a health 
facility. Blood samples were taken from 502 (75%) people, of whom 132 (26%) reported taking AEDs, but 189 (38%) 
had AEDs detectable in the blood. The sensitivity and speciﬁ city of self-reported adherence compared with AEDs 
detected in blood were 38·1% (95% CI 31·1–45·4) and 80·8% (76·0–85·0). The epilepsy treatment gap was 62·4% 
(58·1–66·6). In multivariable analysis, failure to seek biomedical treatment was associated with a patient holding 
traditional animistic religious beliefs (adjusted odds ratio 1·85, 95% CI 1·11–2·71), reporting negative attitudes 
about biomedical treatment (0·86, 0·78–0·95), living more than 30 km from health facilities (3·89, 1·77–8·51), 
paying for AEDs (2·99, 1·82–4·92), having learning diﬃ  culties (2·30, 1·29–4·11), having had epilepsy for longer 
than 10 years (4·60, 2·07–10·23), and having focal seizures (2·28, 1·50–3·47). Reduced adherence was associated 
with negative attitudes about epilepsy (1·10, 1·03–1·18) and taking of AEDs for longer than 5 years (3·78, 1·79–7·98).
Interpretation The sensitivity and speciﬁ city of self-reported adherence is poor, but on the basis of AED detection in 
blood almost two-thirds of patients with epilepsy were not on treatment. Education about epilepsy and making AEDs 
freely available in health facilities near people with epilepsy should be investigated as potential ways to reduce the 
epilepsy treatment gap.
Funding Wellcome Trust.
Introduction
More than 62 million people with epilepsy live in 
countries with low and middle incomes1 and most of 
them do not receive appropriate treatment, an issue 
known as the epilepsy treatment gap.2 The epilepsy 
treatment gap is deﬁ ned as the number of people with 
active epilepsy who have not accessed biomedical services 
(ie, epilepsy not diagnosed) or who are not on treatment 
or are on inadequate treatment, expressed as a percentage 
of the total number with active epilepsy.2 In a systematic 
review of studies done in countries with low and middle 
incomes, the overall estimate of the epilepsy treatment 
gap based on self-reporting was 56%, but the 95% CI was 
wide, ranging from 31% to 100%, with a higher 
proportion in rural areas than in urban areas.3 A more 
recent review reported an epilepsy treatment gap of more 
than 75% in low-income countries compared with less 
than 10% in high-income countries.4
The epilepsy treatment gap could be caused by poor 
access to diagnosis and treatment of epilepsy or non-
adherence to antiepileptic drugs (AEDs). Adherence to a 
drug regimen is deﬁ ned as the extent to which patients take 
drugs as prescribed by their health-care providers.5 
Unintentional non-adherence might be due to forget-
fulness or inability to follow treatment instructions because 
of poor understanding or impairment (eg, poor eyesight), 
whereas intentional non-adherence arises when the patient 
rejects either the doctor’s diagnosis or recommended 
treatment. Between 25% and 75% of people with epilepsy 
do not follow prescribed drug regimens, leading to 
uncontrolled seizures and reduced quality of life.6
Health-care seeking behaviour and adherence are 
complex issues aﬀ ected by many factors. They can be 
explored with Andersen’s behavioural model,7 which 
considers that health service use and adherence are a 
function of four categories: health-care system factors 
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(eg, distance to health facilities); predisposing factors 
(eg, health beliefs); enabling factors (eg, transportation); 
and need, which refers to severity of illness and whether 
people judge their illness to be of suﬃ  cient magnitude 
to consult health services.
We determined the treatment gap, investigated the 
reliability of self-reporting of adherence, and examined 
factors associated with failure to seek biomedical treat-
ment and non-adherence in people with epilepsy in a 
rural area of Kenya.
Methods
Participants
We undertook a cross-sectional survey and risk-factor 
analysis of the epilepsy treatment gap. The study was 
done in the Kiliﬁ  health and demographic surveillance 
system (KHDSS) with 233 881 residents in 2008.8 The 
residents are mainly Mijikenda, a Bantu group of nine 
tribes with Giriama (45%) dominating. The average per 
head income is about 700 Kenyan Shillings (KES; 
US$8) per month and about 55% of the population is 
regarded as poor. Most people (80%) depend on 
subsistence farming. Literacy is low (45%).9 KHDSS is 
served by one district hospital (Kiliﬁ  District Hospital, 
KDH), one health centre, and 12 dispensaries. KDH 
serves as a primary care centre and ﬁ rst-level referral 
facility for the district and stocks four AEDs: 
phenobarbital, phenytoin, carbamazepine, and sodium 
valproate. The health centres and dispensaries stock 
only phenobarbital.
People with epilepsy were identiﬁ ed in a three-stage 
cross-sectional survey that was done to establish the 
prevalence of active convulsive epilepsy as previously 
described.10 In the ﬁ rst stage, household heads were 
asked if anybody in the household had convulsions. 
People who were reported to have seizures were 
interviewed with an epilepsy-speciﬁ c questionnaire11 
and those who were classed as positive were invited to 
be assessed by a clinician. Active convulsive epilepsy 
was deﬁ ned as two or more unprovoked tonic or clonic 
seizures in a lifetime, of which at least one seizure was 
within the 12 months preceding the survey, since this 
criterion is used for prescription of AEDs in Kenya,12 is 
used in other parts of Africa,13,14 and is recommended 
by the International League Against Epilepsy for 
calculation of the treatment gap,2,15 and there is poor 
documentation of previous seizures and recall beyond 
a year in this region. The study was reviewed and 
approved by the Kenya Medical Research Institute and 
national scientiﬁ c and ethical review committees and 
the Swiss Tropical and Public Health Research 
Committee. All participants or their carers provided 
written informed consent.
Procedures
Questionnaires based on those used in previous studies 
of epilepsy in this area10,16–19 and elsewhere20,21 were 
developed in English and translated into local languages. 
In addition to the outcomes of not seeking treatment 
and non-adherence to AEDs, we obtained data for 
several other items: demographic details of the person 
with epilepsy (age and sex), social characteristics 
(religion,22 education, occupation, and marital status) of 
either the person with epilepsy or their carer if the carer 
made decisions about seeking treatment and taking 
AEDs if prescribed; socioeconomic data for the house-
holds based on assets;23 accessibility factors (distance 
from home to health facility, and payment for AEDs); 
severity of epilepsy (duration of epilepsy, seizure 
frequency, type of seizures, and injury during a seizure); 
Figure: Study proﬁ le
KHDSS=Kiliﬁ  health and demographic surveillance system. AED=antiepileptic drug. *Complete data available for 
341 participants: 172 judged to be adherent on the basis of AED detection in blood, 169 did not have AED 
detected in blood. 
393 reported seeking treatment 109 did not report seeking treatment
502 had blood tests*
177 had AEDs detected 
         in blood
216 did not have AEDs 
         detected in blood
12 had AEDs detected 
      in blood
97 did not have AEDs 
      detected in blood
171 did not have blood tests
499 reported seeking treatment 174 did not report seeking treatment
385 reported taking AEDs
         179 adherent according to 
                  Morisky score
         206 not adherent according 
                  to Morisky score
114 did not report taking AEDs
233 881 people living in KHDSS region
1705 not included in survey
232 176 included in survey
231 477 not identiﬁed as people 
                 with epilepsy
699 people with epilepsy identiﬁed
26 not interviewed
       7 refused
       9 moved from area
       2 died
       8 denied having epilepsy
673 interviewed
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stigma; and beliefs and attitudes about epilepsy. People 
with learning diﬃ  culties were deﬁ ned as those who 
were not orientated for person, place, or the period of 
day (morning or afternoon) and who had diﬃ  culty 
following instructions—eg, ﬁ nger nose test—without a 
neuro logical deﬁ cit as assessed by the clinician. For 
analysis of non-adherence, details of prescribed regimen 
were obtained (number of prescribed AEDs, frequency 
of taking AEDs per day, side-eﬀ ects of AEDs, and 
number of years a person with epilepsy has taken 
AEDs). The ﬁ eld staﬀ  administered questionnaires to all 
people with a conﬁ rmed diagnosis of active convulsive 
epilepsy after written informed consent. If the person 
with epilepsy was a child or cognitively im paired adult, a 
caregiver was interviewed. For the risk factor analysis, 
people who sought biomedical treatment were 
compared with those who had not sought treatment, 
and those who adhered (assessed by presence of AEDs 
Sought 
biomedical 
treatment 
(n=499)
Never sought 
biomedical 
treatment 
(n=174)
Odds ratio* 
(95% CI)
p value
Sex
Female 239 (48%) 93 (53%) 1·0 ··
Male 260 (52%) 81 (47%) 0·81 (0·57–1·14) 0·227
Religion
Christianity 237 (47%) 58 (33%) 1·0 ··
Islam 58 (12%) 23 (13%) 1·65 (0·94–2·90) 0·081
Traditional 204 (41%) 93 (53%) 1·83 (1·26–2·68) 0·002
Education
None 231 (46%) 75 (43%) 1·0 ··
Primary 227 (45%) 89 (51%) 1·28 (0·89–1·84) 0·178
Secondary 31 (6%) 9 (5%) 0·96 (0·44–2·13) 0·927
Tertiary 10 (2%) 1 (1%) 0·26 (0·03–2·09) 0·207
Marital status
Single 97 (19%) 20 (11%) 1·0 ··
Married 313 (63%) 121 (70%) 1·97 (1·16–3·34) 0·012
Separated 9 (2%) 2 (1%) 0·94 (0·18–4·75) 0·940
Divorced 27 (5%) 12 (7%) 2·18 (0·94–5·02) 0·068
Widowed 53 (11%) 19 (11%) 1·65 (0·81–3·39) 0·168
Occupation
Subsistence 
farmer
271 (54%) 102 (59%) 1·0 ··
Trader 111 (22%) 34 (20%) 0·85 (0·54–1·33) 0·473
Casual 41 (8%) 20 (11%) 1·30 (0·73–2·33) 0·372
Other 76 (15%) 18 (10%) 0·60 (0·34–1·06) 0·079
Socioeconomic status
Least poor 110 (22%) 24 (14%) 1·0 ··
Less poor 95 (19%) 39 (22%) 0·99 (0·58–1·71) 0·981
Poor 94 (19%) 40 (23%) 1·21 (0·71–2·01) 0·489
Very poor 97 (19%) 35 (20%) 1·15 (0·68–1·97) 0·599
Most poor 103 (21%) 36 (21%) 0·62 (0·35–1·11) 0·108
Beliefs about causes of epilepsy†
Median 8 (5–10) 8 (4–10) 0·90 (0·85–0·95) 0·0002
Beliefs about biomedical treatment†
Median 16 (15–16) 16 (14–16) 0·84 (0·78–0·91) <0·0001
Beliefs about cultural treatment†
Median 12 (8–15) 12 (7–15) 0·98 (0·94–1·01) 0·243
Risk and safety concerns about epilepsy†
Median 8 (8–8) 8 (7–8) 0·90 (0·79–1·02) 0·109
Stereotype about epilepsy†
Median 8 (6–12) 8 (5–12) 1·00 (0·96–1·04) 0·915
Stigma scores‡
Median 7 (2–13) 6 (2–12) 0·98 (0·96–1·01) 0·131
(Continues in next column
Sought 
biomedical 
treatment 
(n=499)
Never sought 
biomedical 
treatment 
(n=174)
Odds ratio* 
(95% CI)
p value
(Continued from previous column)
Distance to health facility
<10 km 177 (35%) 36 (21%) 1·0 ··
10–19 km 169 (34%) 65 (37%) 1·82 (1·15–2·89) 0·011
20–30 km 127 (25%) 51 (29%) 1·91 (1·18–3·11) 0·009
>30 km 26 (5%) 22 (13%) 4·02 (2·04–7·89) 0·021
Payment for AEDs
No 195 (39%) 32 (18%) 1·0 ··
Yes 304 (61%) 142 (82%) 2·92 (1·91–4·48) <0·0001
Learning diﬃ  culties
No 346 (69%) 146 (84%) 1·0 ··
Yes 153 (31%) 28 (16%) 2·23 (1·42–3·50) 0·0005
Duration of epilepsy
<1 year 18 (4%) 26 (15%) 1·0 ··
1–5 years 167 (33%) 70 (40%) 1·05 (0·62–1·78) 0·086
6–10 years 121 (24%) 28 (16%) 2·03 (1·32–3·19) 0·001
>10 years 193 (39%) 50 (29%) 7·20 (3·57–14·5) <0·0001
Number of seizures in past 3 months
None 146 (29%) 63 (36%) 1·0 ··
1–3 166 (33%) 54 (31%) 0·73 (0·47–1·12) 0·144
4–6 72 (14%) 22 (13%) 0·72 (0·41–1·23) 0·246
>6 115 (23%) 35 (20%) 0·71 (0·44–1·16) 0·170
Focal seizures
No 157 (31%) 88 (51%) 1·0 ··
Yes 342 (69%) 86 (49%) 2·15 (1·51–3·07) <0·0001
Injury during seizure
No 230 (46%) 102 (59%) 1·0 ··
Yes 269 (54%) 72 (41%) 0·50 (0·35–0·72) 0·0002
Data are number of patients (%), median (IQR), odds ratio (95% CI), or p value. 
AED=antiepileptic drug. For the variables of religion, education, marital status, 
occupation, socioeconomic status, beliefs and attitudes, and stigma scores, the 
information pertains to either the person with epilepsy, or if the person with 
epilepsy was a child or cognitively impaired, to the carer, since the carer made the 
decision about treatment seeking and giving the AED.*Adjusted for age. †Scores 
of the Kiliﬁ  belief and attitude scale were based on a Likert scale (0=not at all, 
1=believe a little, 2=totally believe), which were summated for the subscale score; 
higher scores represent more positive beliefs about biomedical treatment.26 
‡Scores of the Kiliﬁ  stigma scale for epilepsy were based on a Likert scale (0=not at 
all, 1=sometimes, 2=always), which were summated; higher scores represent 
more stigmatisation.25
Table 1: Univariate analysis of factors associated with failure to seek 
biomedical treatment
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in blood) were compared with those who did not have 
AEDs detected in their blood.
Data were obtained from households for assets and 
indicators of household characteristics such as livestock 
and source of energy for cooking and lighting. Principal 
component analysis was done to construct a homestead 
wealth assets index from the range of assets and household 
characteristics.24 Households were classiﬁ ed into socio-
economic status quintiles on the basis of this index.23
Perceived stigma and epilepsy beliefs and attitudes 
were measured with Likert scales. The Kiliﬁ  stigma 
scale for epilepsy had 15 questions and measured only 
perceived stigma.25 The Kiliﬁ  epilepsy beliefs and attitude 
scale had 34 questions, divided into ﬁ ve sub scales: causes 
of epilepsy, biomedical treatment of epilepsy, cultural 
treatment of epilepsy, risk and safety concerns, and 
negative stereotypes about epilepsy.26
To calculate distance to health facilities, homesteads 
and health facilities were mapped with a global 
positioning system and the Euclidean distance was 
calculated with the coordinates as a reﬂ ection of the time 
taken to travel the distance. The health facility used was 
deﬁ ned as the one where people with epilepsy reported 
seeking treatment most frequently. Treatment-seeking 
behaviour was established by asking whether the person 
had ever sought treatment for epilepsy from a health 
facility before the 2008 epidemiological survey. People 
answering “yes” were asked to identify the health facility 
from which they sought treatment.
Questions were asked about the AEDs that patients 
were currently taking (actual tablets were shown on a 
board to aid recognition). Reported adherence was 
assessed with the Morisky medication adherence scale, a 
four-item scale with high reliability and validity27 that has 
been used to measure adherence in epilepsy.28,29
To measure adherence, blood samples (2 mL) were 
collected. Phenobarbital was measured in all samples, 
with phenytoin and carbamazepine measured in those 
from participants taking these AEDs, with a TDx FLx 
analyser (Abbott Laboratories, Abbott Park, IL, USA). An 
individual was deﬁ ned as adherent if AEDs were detected 
in their blood, with detectable limits of 1·1 μg/mL for 
phenobarbital, 1·0 μg/mL for phenytoin, and 0·5 μg/mL 
for carbamaze pine. Since the half-lives of phenytoin and 
carbamazepine (the AEDs with the shortest elimination 
half-lives used in this area) are greater than 5 h,30 and it 
takes at least ﬁ ve half-lives to clear the drug after one dose, 
the absence of AED in the blood suggests that the drug 
has not been taken within at least the 24 h before the blood 
sample was taken. The optimum therapeutic ranges were 
deﬁ ned as 10–40 μg/mL for phenobarbital, 10–20 μg/mL 
for phenytoin, and 4–12 μg/mL for carbamazepine.31
Odds ratio* (95% CI) p value
Predisposing factors
Religion
Christian 1·0 ··
Islam 1·52 (0·79–2·91) 0·211
Traditional 1·85 (1·11–2·71) 0·015
Negative beliefs about 
biomedical treatment
0·86 (0·78–0·95) 0·003
Health-care system factors
Distance to health facility
<10 km 1·0 ··
10–19 km 1·56 (0·92–2·62) 0·097
20–30 km 1·93 (1·11–3·35) 0·019
>30 km 3·89 (1·77–8·51) 0·0007
Enabling factors
Payment for AEDs
No 1·0 ··
Yes 2·99 (1·82–4·92) <0·0001
Need-speciﬁ c and disease-speciﬁ c factors
Learning diﬃ  culties
No 1·0 ··
Yes 2·30 (1·29–4·11) 0·005
Duration of epilepsy
<1 year 1·0 ··
1–5 years 0·72 (0·40–1·30) 0·280
6–10 years 1·08 (0·63–1·87) 0·764
>10 years 4·60 (2·07–10·23) <0·0001
Focal seizures
No 1·0 ··
Yes 2·28 (1·50–3·47) 0·0001
AED=antiepileptic drug. For the variables of religion, beliefs, and attitudes 
about epilepsy, the information pertains to either the person with epilepsy, or if 
the person with epilepsy was a child or cognitively impaired, to the carer, since 
the carer made the decision about treatment seeking and giving the AED. 
*Adjusted for age. 
Table 2: Multivariable analysis of factors associated with failure to seek 
biomedical treatment
Patients 
who 
answered 
“No”*
Patients with 
AED detected in 
blood who 
answered “No”†
κ‡
Do you ever forget to take your 
medication?
112 (29%) 41 (37%) –0·048
Are you careless at times about 
taking your medication?
114 (30%) 37 (32%) 0·099
When you feel better, do you 
sometimes stop taking your 
medication?
44 (11%) 19 (43%) –0·004
Sometimes, if you feel worse 
when you take your 
medication, do you stop taking 
it?
29 (8%) 13 (45%) –0·022
Data are n (%), n, %, or κ. AED=antiepileptic drug. *Percentages of the 385 people 
with epilepsy who were prescribed AEDs and they or their carer was able to answer 
the questions on the Morisky scale. †Percentages of the participants who had 
answered “No” to the relevant Morisky question. ‡κ score of “No” on Morisky 
scale versus detectable blood concentrations of AEDs.
Table 3: Adherence as assessed with the self-reported Morisky scale 
compared with that as assessed by detection of AEDs in blood samples
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Statistical analysis
Data were double-entered and veriﬁ ed with a MySQL 
V5 database. Statistical analyses were done with Stata 
versions 11 and 12. We investigated treatment seeking for 
all study participants interviewed, whereas non-adherence 
was investigated only in those who reported taking AEDs 
and gave a blood sample. The epilepsy treatment gap was 
deﬁ ned as the number of people with active epilepsy who 
had not accessed biomedical services or who were not on 
treatment or were on inadequate treatment, expressed as 
a percentage of the total number with active epilepsy.2 The 
sensitivity, speciﬁ city, and con ﬁ dence intervals were 
calculated in Stata. Concordance was assessed between 
self-reported adherence and AED detection in blood with 
the κ statistic. In exploratory analyses, we examined the 
distributions of the dependent variables before selecting 
the appropriate test statistic. We used Pearsons’ χ² test to 
measure associations between categorical socio demo-
graphic characteristics and failure to seek treatment or 
non-adherence.
Univariate associations for two outcomes (failure to 
seek treatment or non-adherence to AED) were inves-
tigated with logistic regression, adjusted for age. We 
included variables with p≤0·20 in a multivariable model 
using a backward elimination process. Variables with 
p≤0·05 in multivariable analysis were retained in the 
ﬁ nal model. Attributable fractions were calculated with 
the ﬁ nal multivariable logistic regression model by a 
user-written command “punaf” in STATA version 12.32,33
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in this study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The epidemiological survey included 232 176 (99%) of 
233 881 people living in the KHDSS region during 2008. 
699 people with epilepsy were identiﬁ ed, of whom 
673 (96%) were interviewed (ﬁ gure). 392 (58%) 
participants were younger than 18 years. Many adults 
(133 [47%]) had no formal education.
Of the 673 people with epilepsy who were interviewed, 
499 (74%) reported seeking treatment for epilepsy from a 
health facility, of whom 395 (79%) used KDH as their 
primary source of AEDs (appendix p 1). 502 (75%) gave 
blood samples. People who did not give blood samples 
were signiﬁ cantly younger, were more likely to have 
traditional religious (animist) beliefs, were more likely to 
believe that epilepsy responds to biomedical treatment, 
were more likely to be married (if adults), less likely to pay 
for AEDs, had epilepsy for a shorter period, had less fre-
quent seizures, and were less likely to injure themselves 
during the seizures compared with people who provided 
samples (appendix pp 2–3). Of the 502 people in whom 
Non-adherent people 
(n=172)
Adherent people 
(n=169)
Odds ratio* 
(95% CI)
p value
Sex
Female 74 (43%) 82 (49%) 1·0 ··
Male 98 (57%) 87 (51%) 1·25 (0·81–1·92) 0·299
Religion
Christianity 85 (49%) 91 (54%) 1·0
Islam 23 (13%) 18 (11%) 1·38(0·70–2·75) 0·352
Traditional 60 (36%) 64 (37%) 1·13 (0·71–1·79) 0·613
Education
None 70 (41%) 74 (44%) 1·0 ··
Primary 85 (49%) 76 (45%) 1·20 (0·76–1·88) 0·433
Secondary 11 (6%) 16 (9%) 0·75 (0·32–1·74) 0·502
Tertiary 6 (3%) 3 (2%) 2·03 (0·48–8·46) 0·336
Marital status
Single 34 (20%) 52 (31%) 1·0 ··
Married 108 (63%) 82 (49%) 2·02 (1·20–3·39) 0·008
Separated 1 (1%) 5 (3%) 0·29 (0·03–2·60) 0·267
Divorced 9 (5%) 10 (6%) 1·40 (0·52–3·81) 0·508
Widowed 20 (12%) 20 (12%) 1·53 (0·72–3·26) 0·270
Occupation of household head
Farmer 90 (52%) 87 (51%) 1·0 ··
Trader 41 (24%) 36 (21%) 1·13 (0·66–1·93) 0·665
Casual 18 (11%) 17 (10%) 1·03 (0·50–2·13) 0·934
Other 23 (13%) 29 (17%) 0·77 (0·42–1·45) 0·428
Social economic status
Least poor 38 (22%) 50 (30%) 1·0 ··
Less poor 36 (21%) 35 (21%) 1·64 (0·77–3·48) 0·196
Poor 36 (21%) 34 (20%) 1·11 (0·55–2·25) 0·774
Very poor 35 (20%) 22 (13%) 1·08 (0·53–2·19) 0·831
Most poor 27 (16%) 28 (17%) 0·79 (0·40–1·55) 0·489
Availability of family support
No 19 (11%) 40 (24%) 1·0 ··
Yes 143 (83%) 129 (76%) 1·58 (0·92–2·71) 0·097
Unknown 10 (6%) 0 ·· ··
Beliefs about causes of epilepsy†
Median 8 (5–10) 8 (6–10) 0·94 (0·87–1·01) 0·113
Beliefs about biomedical treatment†
Median 16 (15–16) 16 (15–16) 0·92 (0·80–1·04) 0·178
Beliefs about cultural treatment†
Median 12 (8–16) 13 (9–16) 0·99 (0·95–1·04) 0·716
Risk and safety concerns about epilepsy†
Median 8 (7–8) 8 (8–8) 0·82 (0·68–0·98) 0·034
Beliefs about epilepsy†
Median 8 (4–11) 10 (6–13) 1·08 (1·03–1·15) 0·002
Stigma scores‡
Median 7 (2–13) 9 (4–15) 0·97 (0·94–1·00) 0·088
Learning diﬃ  culties
No 127 (74%) 107 (63%) 1·0 ··
Yes 45 (26%) 62 (37%) 0·62 (0·39–0·99) 0·047
Distance to health facility
<10 km 44 (26%) 63 (37%) 1·0 ··
10–19 km 61 (35%) 45 (27%) 1·92 (1·11–3·31) 0·019
(Continues on next page)
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blood concentrations of AEDs were measured, 393 
reported seeking treatment, of whom 117 (40%) were on 
polytherapy. Pheno barbital was detected in the blood of 
151 people with epilepsy, phenytoin in 50, and 
carbamazepine in 48. Four patients reported taking 
sodium valproate (which was not measured in blood), but 
two of these patients were taking one of the other AEDs, 
and the other two had not collected their drug from KDH 
(the only source of sodium valproate) within the past 
3 months and were classiﬁ ed as non-adherent. The 
epilepsy treatment gap based on AEDs detected in blood 
samples was 62·4% (95% CI 58·1–66·6).
We studied 19 variables as potential predictors of people 
not seeking biomedical treatment (table 1). Of these, 16 had 
univariate p values of 0·20 or less and were included in the 
multivariable logistic regression model. From the 
multivariable analysis, people with epilepsy were less likely 
to seek treatment if they had traditional animistic religious 
beliefs, had negative attitudes about biomedical treatment, 
lived 20 or more km from where they sought health care, 
reported paying for AEDs, had epilepsy for longer than 
10 years, had learning diﬃ  culties, and had focal seizures 
(table 2). Attributable fraction analysis indicated that 
treatment seeking could improve by 11% (95% CI 1–21) if 
people with epilepsy thought that biomedical treatment 
would help, 40% (21–54) if AEDs were free, and 12% (3–21) 
if the health facilities where people obtained AEDs were 
less than 20 km from their homes.32,33 
Of the 499 people who reported seeking biomedical 
treatment, only 385 (77%) were prescribed AEDs and the 
person with epilepsy or their carer were able to answer 
the questions on the Morisky scale. On the basis of 
Morisky scores, 179 (46%) people with epilepsy were 
adherent (score of 0) and 206 (54%) were non-adherent 
(score >0; table 3). Of the 502 who had AEDs measured 
in blood, 189 (38%) had AEDs detected of whom 72 
reported taking AEDs. In the 313 who did not have any 
AED detected, 60 (19%) reported taking AEDs. 48 (25%) 
of the 189 people with AEDs detected in their blood had 
concentrations in the detectable but not optimum range 
and 141 (75 %) were in the optimum range. Overall, the 
sensitivity and speciﬁ city of reported adherence 
compared with AEDs detected in the blood were 38·1% 
(95% CI 31·1–45·4) and 80·8% (76·0–85·0), respectively. 
The con cordance between self-reported adherence and 
detection in blood for the three prescribed AEDs occurred 
in 72 (55%) of 132 people with epilepsy. There was little 
agreement between adherence as measured by blood 
samples and the Morisky scores.
We studied 25 variables as potential predictors of non-
adherence (table 4). 15 were retained in the multivariable 
logistic regression model. People with epilepsy were 
less likely to adhere if they had negative attitudes such 
as feeling that they were rejected or had taken AEDs for 
more than 5 years (table 5). Attributable fraction analysis 
indicated that adherence could be improved by 20% 
(95% CI 7–30) if attitudes could be modiﬁ ed.
Discussion
In Kenyans with active convulsive epilepsy who had 
similar characteristics to people with epilepsy in other 
parts of Africa,3,34 we found that the epilepsy treatment 
Non-adherent people 
(n=172)
Adherent people 
(n=169)
Odds ratio* (95% 
CI)
p value
(Continued from previous page)
20–30 km 58 (34%) 49 (29%) 1·70 (0·99–2·94) 0·053
>30 km 9 (5%) 12 (7%) 1·07 (0·41–2·75) 0·893
Good relation with health-care provider
No 19 (11%) 24 (14%) 1·0 ··
Yes 153 (89%) 145 (86%) 1·34 (0·70–2·55) 0·374
Payment for AEDs
No 116 (67%) 88 (52%) 1 ··
Yes 56 (33%) 81 (48%) 1·97(1·26–3·06) 0·003
AEDs stored out of sight
No 127 (74%) 107 (63%) 1·0 ··
Yes 45 (26%) 62 (37%) 1·62 (1·02–2·57) 0·043
Duration of epilepsy
<1 years 4 (2%) 1 (1%) 1·0 ··
1–9 years 91 (53%) 87 (51%) 0·26 (0·03–2·41) 0·238
10–20 years 51 (30%) 60 (36%) 0·21 (0·02–1·97) 0·173
>20 years 26 (15%) 21 (12%) 0·30 (0·03–2·88) 0·294
Focal seizures
No 54 (31%) 50 (30%) 1·0 ··
Yes 118 (69%) 119 (70%) 0·91 (0·57–1·45) 0·683
Number of seizures in past 3 months
None 46 (27%) 42 (25%) 1·0 ··
1–3 68 (40%) 44 (26%) 1·41 (0·80–2·49) 0·230
4–6 28 (16%) 28 (17%) 0·92 (0·47–1·81) 0·811
>6 30 (17%) 55 (33%) 0·50 (0·27–0·93) 0·029
Duration of AED treatment
<1 year 49 (28%) 17 (10%) 1·0 ··
1–3 years 52 (30%) 48 (28%) 1·68 (0·83–3·39) 0·147
4–5 years 21 (12%) 21 (12%) 1·80 (1·06–3·04) 0·029
>5 years 50 (29%) 83 (49%) 4·76 (2·47–9·15) <0·0001
Number of AEDs
Monotherapy 115 (67%) 87 (51%) 1·0
Polytherapy 57 (33%) 82 (49%) 0·52 (0·34–0·81) 0·004
Reported side-eﬀ ects of AEDs
No 156 (91%) 157 (93%) 1·0
Yes 16 (9%) 12 (7%) 1·36 (0·62–2·96) 0·460
Injury during seizure
No 69 (40%) 54 (32%) 1·0
Yes 103 (60%) 115 (68%) 0·65 (0·41–1·04) 0·071
Data are number of patients (%), median (IQR), odds ratio (95% CI), or p value. The 341 patients included in this table are 
drawn from the 393 who reported seeking treatment, and had more than 90% data available for the variables examined. 
For the variables of religion, education, marital status, occupation, socioeconomic status, beliefs and attitudes, and stigma 
scores, the information pertains to either the person with epilepsy, or if the person with epilepsy was a child or cognitively 
impaired, to the carer, since the carer made the decision about treatment seeking and giving the AED. AED=antiepileptic 
drug. *Adjusted for age. †Scores of the Kiliﬁ  belief and attitude scale were based on a Likert scale (0=not at all, 1=believe a 
little, 2=totally believe), which were summated for the subscale score; higher scores represent more positive beliefs about 
biomedical treatment.26 ‡Scores of the Kiliﬁ  stigma scale for epilepsy were based on a Likert scale (0=not at all, 
1=sometimes, 2=always), which were summated; higher scores represent more stigmatisation.25
Table 4: Univariate analysis of factors associated with non-adherence to AEDs
See Online for appendix
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gap was 62% as measured by detection of AEDs in 
blood samples. This ﬁ nding represents a reduction 
from 74% measured during a survey in 200310 and could 
be attributed to setting up an epilepsy clinic with a 
continuous supply of AEDs and sensitisation of the 
community. However, the sensitivity and spe ciﬁ city of 
self-reporting remained poor. The factors associated 
with reduced treatment seeking are diﬀ erent to those 
associated with reduced adherence to AEDs. Modiﬁ able 
risk factors for failure to seek treatment are negative 
attitudes about biomedical treatment, payment for 
AEDs, and distance from health facilities providing 
AEDs. Adherence to AEDs could be improved by re-
duction of negative attitudes to epilepsy (panel).
People with epilepsy who held traditional animistic 
religious beliefs were less likely to seek biomedical 
treatment than were Christians and Muslims, possibly 
because of misconceptions and superstitions associated 
with epilepsy in Kiliﬁ .35 People with epilepsy with nega-
tive beliefs and attitudes about biomedical treatment of 
epilepsy were less likely to seek treatment from health 
facilities, suggesting that modiﬁ cation of patients’ beliefs 
and attitudes is an important step in improvement of 
treatment seeking.36,37
Other factors associated with failure to seek treatment 
were distance to health facilities and payment for AEDs. 
The geographical proximity of health services to people’s 
homes is an important factor that aﬀ ects use of health 
services, particularly in resource-poor settings where 
density of biomedical health facilities is often low. The 
1997 Kenyan health policy strategic framework states 
that all households should have access to health services 
within a 5 km range.38 In KHDSS, there is a high density 
of biomedical health facilities within reach by people 
with epilepsy, but only KDH has an epilepsy clinic with 
a continuous supply of AEDs and AEDs other than 
pheno barbital. The erratic supplies of AEDs in the 
peripheral clinics (JAC, unpublished) might have 
reduced the use of these peripheral facilities. People 
with epilepsy who reported paying for AEDs were less 
likely to seek treatment than were people who did not 
pay. The cost of AEDs in peripheral facilities was 10 KES 
(US$0·13) for a 1-month supply of phenobarbital in 
2008, whereas at KDH it was 40 KES ($0·51). This cost 
of AEDs, although small, is signiﬁ cant when combined 
with indirect costs of seeking care—eg, transport costs.
Of the epilepsy-speciﬁ c factors, people with epilepsy 
who had seizures for more than 10 years might be less 
likely to seek treatment compared with people with 
disease of shorter duration because they had learnt to 
cope with their disorder. People with focal seizures were 
less likely to seek treatment than were those with 
generalised seizures, although focal seizures are asso-
ciated with symptomatic causes and are more likely to be 
associated with behavioural problems.39 Most of the 
seizures were focal becoming generalised, and being 
aware at the onset of seizure might have made people 
less inclined to seek treatment because of the stigma. 
People with epilepsy and learning diﬃ  culties were less 
likely to seek treatment, perhaps because they were not 
brought to biomedical facilities by their families or 
because of their diﬃ  culties in understanding the 
importance of treatment.
Patient self-reporting using reliable and valid ques-
tionnaires is thought to be an eﬃ  cient and cost-eﬀ ective 
method to assess adherence, although some patients 
might underestimate or overestimate their adherence.40 
We found that the sensitivity and speciﬁ city of self-
reporting compared with detection of AEDs in blood 
samples was low, suggesting that self-reporting is not a 
reliable measure of adherence in people with epilepsy in 
this community and probably in many countries with low 
Panel: Research in context
Systematic review
We searched Medline (1966, to May, 2012), ISI Web of 
Science (1966, to May, 2012), and Cochrane reviews with the 
search term “epilepsy treatment gap”. Searches were 
restricted to human studies. We found 281 references, most 
of which we reviewed in a previous paper3 and a recent 
review.4 We reviewed the outstanding 31 references. We 
found that the epilepsy treatment gap was attributed to 
cultural beliefs, inadequate skilled manpower, cost of 
treatment, and unavailability of antiepileptic drugs.
Interpretation
This study showed that self-reporting of adherence to 
antiepileptic drugs (AEDs) might not be reliable in rural 
Africa, and that risk factors for the failure to seek biomedical 
treatment for epilepsy and the poor adherence to prescribed 
treatment are diﬀ erent. Treatment seeking could be 
improved by modiﬁ cation of attitudes to epilepsy and 
provision of free AEDs in health facilities near to the 
residence of the person with epilepsy. Adherence could be 
improved by changes in attitudes towards epilepsy.
Odds ratio* (95% CI) p value
Attitudes
Negative attitudes about epilepsy 1·10 (1·03–1·18) 0·004
Duration of AED treatment
<1 year 1·0
1–3 years 1·75 (0·79–3·87) 0·165
4–5 years 1·79 (0·98–3·29) 0·059
>5 years 3·78 (1·79–7·98) 0·0005
AED=antiepileptic drug. For attitudes about epilepsy, the information pertains to 
either the person with epilepsy, or if the person with epilepsy was a child or 
cognitively impaired, to the carer, since the carer made the decision about 
treatment seeking and giving the AED. *Adjusted for age.
Table 5: Multivariable analysis of factors associated with non-adherence 
to AEDs
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and middle incomes. This ﬁ nding questions the reliability 
of data in systematic reviews of the epilepsy treatment 
gap.3,4 Furthermore, we did not ﬁ nd that the Morisky scale 
was useful for measuring adherence in this population. 
Although the scale has been used in other studies of 
epilepsy,28,29 it has not been compared with AED detection 
in blood. There was no signiﬁ cant diﬀ erence in adherence 
based on blood samples among the diﬀ erent AEDs (data 
not shown), despite the diﬀ erent half-lives (phenobarbital, 
48–168 h; phenytoin, 7–42 h; carbamazepine, 5–26 h).30
Non-adherence was associated with established epilepsy, 
which is in accord with previous reports that people with 
epilepsy who had taken AEDs for a longer duration were 
less likely to adhere.41 Non-adherence was also associated 
with negative beliefs and attitudes about epilepsy as 
reported previously.6
Our study had several limitations. Non-adherence was 
reported at only one timepoint as opposed to monitoring 
over time, which might capture variations such as dif-
ferences in timing of administration, missing doses of 
AEDs, or taking AEDs just before clinical assessment.42 We 
did not study people with non-convulsive epilepsy since 
the survey was designed to capture only those with active 
convulsive epilepsy. Recall and reporting bias of self-
reported answers might have occurred, and there were 
signiﬁ cant diﬀ erences between people who gave blood 
samples for measurement of adherence and those who did 
not. This study was done in an area where we have been 
studying epilepsy since 2003, although the treat ment gap 
is still 62%. We did not control for quality of care, which 
might play a part in determining health service use.
In this rural area of Kenya, almost two-thirds of people 
with epilepsy were not adequately treated and the 
sensitivity and speciﬁ city of self-reported adherence were 
poor. Modiﬁ cation of beliefs and attitudes and pro vision 
of a free and constant supply of AEDs to nearby health 
facilities could substantially reduce the treatment gap. 
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